Two Texas companies with NASA roots team up to help seniors at risk

HOUSTON, July 8, 2020 /PRNewswire-PRWeb/ — Galen Data Inc., a leading cloud platform for medical devices, today announced its newest partnership with Advanced TeleSensors Inc. (ATS), maker of the Cardi/o® touchless monitor. This partnership powers a much-needed technology during the COVID-19 crisis.

The Galen Cloud® turnkey solution gives ATS a secure and FDA-compliant cloud environment along with analytics for data captured by the Cardi/o® monitoring device used to perform remote, touchless vital-sign monitoring of at-risk patients. The Galen Cloud® provides data access and alerts to ATS, individual users, and their care team.

“We wish we had found Galen Data sooner. We had been building our own cloud for six months, thinking a custom solution would best meet our needs” said Sajol Ghoshal, CEO and President of ATS. “Getting up-and-running with them was very easy, and it allowed us to focus on our core competency — which is data-signal processing.”

Cardi/o® uses radio frequency processing to provide remote, touchless monitoring of individuals’ vital signs. The company’s founders, Caltech scientists, developed the core technology behind the product at NASA’s Jet Propulsion Lab. The initial use case for these monitoring devices is in assisted living facilities as well as for at-risk patients in the home setting. Such technologies are especially important now, as seniors are increasingly isolated due to COVID-19 and can benefit from a technology to provide that safety and peace of mind.

The founders of Galen Data have a combined 50+ years of experience in healthcare technology, medical devices, and regulatory compliance. They met while working together for a software contractor building safety systems for NASA. Recognizing that the Internet of Things (IoT) would change the landscape for connected medical devices, its leadership built the first turnkey cloud solution for medical device makers. The company’s platform offers a configurable, secure, and compliant cloud, reducing time, cost, and risk for the medical device maker.

“We knew that our platform would be a great fit for Cardi/o,” Chris DuPont, CEO of Galen Data said. “Speed was critical, accentuated by the COVID-19 crisis. We were well positioned to address ATS’ needs, and help those at-risk in the process.”

About Galen Data, Inc.
Galen Data, Inc. provides a turnkey cloud solution for medical device makers that is configurable, secure, and compliant. The company was founded to make device-to-cloud connectivity possible in a matter of weeks instead of months, and at a fraction of the cost. The Galen Cloud™ collects and securely stores data, and includes tools to visualize and analyze that data. Dashboards and alerts for the manufacturer, medical team, and patients are also provided within the platform. The software platform is compliant to FDA, HIPAA, and CE Mark standards, and is ISO13485:2016 certified. Dozens of companies have partnered with Galen Data to solve their medical device connectivity needs.

About Advanced TeleSensors, Inc.
Advanced TeleSensors (ATS) is the maker of Cardi/o® Remote Cardiac Monitor: no wires, no wearables, no hassles. ATS is a privately held corporation headquartered in Austin, TX. Cardi/o® RF sensor technology was invented at NASA’s Jet Propulsion Lab by Caltech scientists, the founders of Advanced Telesensors. The founders’ world-class expertise in RF signal processing drove the innovation from incubation toward commercialization under CEO Sajol Ghoshal, a startup veteran with $3B in successful exits.

Contact:
Mosheh Poltorak
Galen Data, Inc
346-301-0399
mosheh@galendata.com
http://www.galendata.com    

Stephanie Probasco
Cardi/o by Advanced TeleSensors, Inc.
(888) 292-2208, ext 708
sprobasco@cardio.io
http://www.cardio.io

###

 

SOURCE Galen Data

Staff

Recent Posts

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

1 hour ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

1 hour ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

1 hour ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

4 hours ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

4 hours ago